Nippon Life Global Investors Americas Inc. lessened its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 19.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 42,080 shares of the company's stock after selling 10,270 shares during the period. Nippon Life Global Investors Americas Inc.'s holdings in AbbVie were worth $10,589,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of ABBV. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the 4th quarter worth approximately $28,000. Imprint Wealth LLC grew its holdings in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after buying an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID raised its position in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after buying an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie during the fourth quarter valued at approximately $31,000. Finally, Abound Financial LLC purchased a new position in shares of AbbVie in the fourth quarter worth $32,000. 70.23% of the stock is owned by institutional investors.
Key AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Billionaire investor Ken Griffin increased his AbbVie position by 547% in the second quarter, highlighting institutional confidence in the company’s high dividend yield and relatively defensive business profile. Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2
- Positive Sentiment: AbbVie’s immunology franchise remains a key growth anchor, while newer medicines and its oncology pipeline are helping diversify the company beyond Humira and support its longer-term outlook. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
- Positive Sentiment: Recent quarterly results exceeded analyst expectations, with revenue up 10.2% year over year and earnings modestly ahead of consensus. Management’s third-quarter earnings outlook also points to continued operating momentum.
- Neutral Sentiment: Analysts see AbbVie and Eli Lilly as offering different combinations of growth, pipeline potential and risk; the comparison reinforces that AbbVie is viewed more as a dividend and established-product investment than a high-growth pharmaceutical story. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
- Negative Sentiment: Valuation is the main near-term concern. After its strong run, AbbVie trades at an elevated earnings multiple, leaving less room for disappointment if growth slows or pipeline investments take longer to pay off. Has AbbVie Stock Become Too Expensive to Buy?
- Negative Sentiment: Second-quarter oncology sales declined 2.4%, primarily because of falling Imbruvica revenue. Growth from Venclexta and newer products only partially offset that pressure, raising concerns about the pace of AbbVie’s portfolio transition. How Did ABBV’s Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?
AbbVie Price Performance
Shares of ABBV stock opened at $263.08 on Thursday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The stock's 50 day simple moving average is $251.04 and its two-hundred day simple moving average is $228.43. The company has a market cap of $464.81 billion, a PE ratio of 74.32, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30.
AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie Inc. will post 14.06 EPS for the current year.
AbbVie Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is presently 195.48%.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on ABBV shares. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. BNP Paribas Exane increased their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Bank of America lifted their target price on AbbVie from $234.00 to $276.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Finally, DZ Bank upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.
View Our Latest Research Report on AbbVie
Insiders Place Their Bets
In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.
About AbbVie
(
Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
